Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.51 |
| ▸ | HTR1A | P08908 | 4/20 | 0.48 |
| ▸ | RORC | P51449 | 4/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | PAK4 | O96013 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6636075 | 0.93 | SLC6A4 (0.53) | SLC6A4HTR1ARORCDRD2BRD4 | |
| Ethylene SCHEMBL7478496 | 0.90 | SLC6A4 (0.51) | SLC6A4HTR1ARORCDRD2BRD4 | |
| SCHEMBL6088807 | 0.85 | SLC6A4 (0.54) | SLC6A4HTR1ARORCCNR1CNR2 | |
| SCHEMBL6639237 | 0.82 | SLC6A4 (0.43) | SLC6A4HTR1ARORCDRD2BRD4 | |
| SCHEMBL3889328 | 0.81 | DRD2 (0.58) | SLC6A4HTR1ARORCDRD2 | |
| SCHEMBL6637096 | 0.80 | HTR1A (0.53) | SLC6A4HTR1ARORCDRD2CNR1 | |
| SCHEMBL6639951 | 0.77 | HTR1A (0.52) | SLC6A4HTR1ARORCCNR1CNR2 | |
| SCHEMBL6637786 | 0.77 | SLC6A4 (0.50) | SLC6A4HTR1ARORCBRD4CREBBP | |
| SCHEMBL6635822 | 0.77 | SLC6A4 (0.56) | SLC6A4HTR1ARORCCNR1CNR2 | |
| SCHEMBL7972314 | 0.76 | SLC6A4 (0.44) | SLC6A4HTR1ARORCCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488751-B2 | Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-benzodioxan | WYETH (US) | 2009-02-10 | — | — | US | disclosed |
| US-20060160881-A1 | Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-benzodioxan | WYETH (US) | 2006-07-20 | — | — | US | disclosed |
| US-20060148881-A1 | Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-Benzodioxan | WYETH (US) | 2006-07-06 | — | — | US | disclosed |
| US-7049314-B2 | Sexual disorders; antidepressants; attention deficit hyperactivity, obsessive-compulsive, and/or post-traumatic stress disorder; drug abuse and addiction | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-23 | — | — | US | disclosed |
| US-7041697-B2 | Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-benzodioxan | WYETH (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1537103-A1 | ANTIDEPRESSANT CYCLOALKYLAMINE DERIVATES OF 2,3-DIHYDRO-1,4-BENZODIOXAN | Wyeth (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20040127543-A1 | Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-benzodioxan | WYETH | 2004-07-01 | — | — | US | disclosed |
| US-20040077705-A1 | Cyclopentyl indole derivatives | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | disclosed |
| WO-2004026236-A2 | CYCLOPENTYL INDOLE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
| WO-2004024723-A1 | ANTIDEPRESSANT CYCLOALKYLAMINE DERIVATIVES OF 2,3-DIHYDRO-1,4-BENZODIOXAN | WYETH (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160881-A1 | Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-benzodioxan | HTR5A, OPRD1, DRD2 | SLC6A4 66/4885HTR1A 31/4885RORC 3305/4885 |
| US-20040077705-A1 | Cyclopentyl indole derivatives | HTR5A, TPH1, TPH2 | SLC6A4 11/4885HTR1A 4/4885RORC 931/4885 |
| US-20040127543-A1 | Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-benzodioxan | HTR5A, OPRD1, TAAR5 | SLC6A4 61/4885HTR1A 24/4885RORC 3439/4885 |
| US-20060148881-A1 | Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-Benzodioxan | HTR5A, OPRD1, DRD2 | SLC6A4 66/4885HTR1A 31/4885RORC 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.